Ventripoint Medical System Plus (VMS+)

by Ventripoint Diagnostics  · Based in Canada → — Ventripoint Diagnostics offers cutting-edge cardiac imaging with AI technology, enhancing heart health diagnostics and patient care globally.
Cardiology Cardiothoracic Surgery Radiology

Contact for pricing
Regulatory Status Disclosed

Overview

The Ventripoint Medical System Plus (VMS+) is an advanced image analysis technology designed to measure heart volume and function for individuals with various cardiovascular conditions. It leverages proprietary Knowledge-Based Reconstruction (KBR) artificial intelligence algorithms to transform standard 2D echocardiograms into high-fidelity 3D models of all four chambers of the heart. This system provides comprehensive cardiac metrics, including volumes and ejection fractions, with an accuracy comparable to cardiac MRI, but at a fraction of the cost and time. VMS+ consists of a portable console, a sensor system, and VMS+ image analysis software, and is compatible with any commercially available 2D ultrasound machine. The latest version, VMS+ 4.0, includes AI-assisted automated point placement to improve user workflow efficiency and magnet-free sensors, enabling its use for patients with cardiac pacemakers who cannot undergo MRI. It is a diagnostic aid that provides a point-of-care solution to better communicate the heart’s structure and function, supporting clinical decision-making across various settings.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Transforms 2D echocardiograms into 3D heart models
  • Provides cardiac metrics for all four chambers of the heart (volumes, ejection fractions)
  • Utilizes Knowledge-Based Reconstruction (KBR) AI algorithm
  • Offers MRI-equivalent accuracy for cardiac measurements
  • Compatible with any commercially available 2D ultrasound system
  • Features AI-assisted automated point placement for improved workflow
  • Includes magnet-free sensors (VMS+ 4.0)
  • Enables use for patients with cardiac pacemakers (VMS+ 4.0)
  • Provides enhanced visualization tools
  • Faster and more cost-effective alternative to cardiac MRI

Use Cases

  • Diagnosis and monitoring of congenital heart defects
  • Assessment of left or right heart failure
  • Monitoring patients with various cardiovascular conditions
  • Reducing the need for MRI in children and adults
  • Cardiac assessment in pediatric and high-anxiety patients
  • Point-of-care solution for heart structure and function analysis

What Physicians Need to Know

Echocardiography AI Features
Ventripoint Medical System Plus (VMS+) transforms 2D echocardiograms into precise 3D heart models using its proprietary Knowledge Based Reconstruction (KBR) algorithm. The VMS+ 4.0 version includes AI-assisted point placement for anatomical landmarks, which simplifies image analysis and enhances accuracy, with users reviewing and adjusting the automatically placed points. The system calculates volumes and ejection fractions for all four cardiac chambers (Left Ventricle, Right Ventricle, Left Atrium, Right Atrium) with accuracy comparable to cardiac MRI (cMRI). It is designed to provide accurate results even from poor quality or sparse 2D echo images and reduces operator-dependent variability.
Cardiac CT/MRI Analysis
VMS+ serves as an alternative to cardiac MRI (cMRI) by providing MRI-equivalent accurate volumetric measurements and ejection fractions from echocardiograms, particularly for the challenging right ventricle. The underlying KBR technology was developed using a database of thousands of cMRIs, encompassing both normal and pathological heart morphologies, including congenital heart conditions. The software can also import 3D datasets and MRI studies for analysis on a personal workstation.
Heart Failure Risk Prediction
VMS+ provides accurate cardiac metrics, including volumes and ejection fractions, which are essential for assessing heart function and monitoring conditions like heart failure. Clinical studies are exploring its use in measuring Left Atrial Enlargement (LAE), which correlates with diastolic dysfunction (heart failure with preserved ejection fraction, HFpEF) and can be an early indicator of heart failure risk. The system facilitates close monitoring of patients, aiding in early diagnoses and treatment decisions.
Cardiac Monitoring Integration
The VMS+ system integrates with any standard 2D echocardiography machine. It utilizes an innovative sensor tracking system that attaches to the ultrasound probe, along with a separate patient sensor, to track 3D spatial coordinates and correct for patient movement. Designed for seamless integration into existing clinical workflows, analysis typically takes minutes. The system supports remote screening and decentralized diagnostics, making advanced cardiac imaging accessible in remote communities. All diagnostic data is designed to remain within the institution's IT and server system by default.
AHA/ACC Guideline Alignment
While not explicitly stating direct alignment with AHA/ACC guidelines, VMS+ provides MRI-equivalent accurate cardiac measurements (volumes and ejection fractions for all four chambers), which are fundamental data points used in guideline-driven patient management and diagnosis.
Physician Tip

VMS+ offers a valuable tool for cardiologists seeking MRI-equivalent volumetric and ejection fraction measurements from standard 2D echocardiograms, particularly for all four heart chambers, including the often-challenging right ventricle. Its AI-assisted point placement streamlines analysis, making it a faster, more accessible, and cost-effective alternative to cMRI, especially beneficial for pediatric patients or those requiring frequent monitoring. The system's ability to work with various ultrasound machines and integrate into existing workflows makes it a practical point-of-care solution for diagnosis and longitudinal monitoring across a wide spectrum of cardiac conditions. It can also aid in identifying patients at risk for heart failure by enabling precise LAE measurements.

Ventripoint Medical System Plus (VMS+) is designed for broad compatibility, integrating with any commercially available 2D ultrasound system. It can be installed on any personal workstation and accepts ultrasound images via a video output. The system's architecture ensures that all diagnostic data remains within the institution's own IT and server system by default, addressing data security and privacy concerns. Furthermore, VMS+ supports the import of existing 3D echo and MRI datasets for analysis, enhancing its utility within diverse clinical imaging environments. The use of magnet-free sensors simplifies the acquisition process by eliminating the need for calibration and allowing for patient repositioning during the exam.

Details

Category Cardiology AI, Radiology & Imaging AI
Pricing Contact for pricing
DeploymentPortable console, sensor system, and VMS+ image analysis software; software can be installed on any personal workstation.
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

VMS+ 4.0 received U.S. FDA 510(k) clearance (K241222) on February 26, 2025, as an Automated Radiological Image Processing Software/System. It is intended to record, analyze, store, and retrieve digital ultrasound images for computerized 3D image processing.

Integrations
EHR Not specified
Specialties Cardiology, Cardiothoracic Surgery, Radiology

What the Web Says

The Ventripoint Medical System Plus (VMS+) is an AI-driven technology that transforms standard 2D ultrasound scans into highly accurate 3D heart models, providing cardiac measurements comparable to MRI. It aims to offer a faster, more affordable, and accessible alternative to cardiac MRI, particularly beneficial for patients who have difficulty tolerating MRI scans, such as children. The system integrates with existing 2D ultrasound machines and is designed to fit seamlessly into clinical workflows.

Overall: Positive

Strengths

  • Provides MRI-equivalent accuracy for cardiac measurements, including all four chambers of the heart.
  • Significantly reduces costs and time compared to cardiac MRI, potentially saving hospitals substantial amounts per scan.
  • Increases accessibility to advanced cardiac diagnostics, especially for children, patients with claustrophobia, or those in remote areas.
  • Compatible with any standard 2D ultrasound system, allowing for easy integration into existing workflows.
  • Non-invasive and does not require sedation or contrast, improving patient comfort and safety.
  • Can generate accurate results even with poor quality ultrasound images.

Limitations

  • More time-consuming than fully automated echocardiography systems due to the need for manual plotting of anatomical points.
  • Some experts believe more evidence is needed from larger-scale studies to routinely use VMS+ in healthcare systems.
  • Limited published data makes it difficult to definitively compare its superiority to current 3D echocardiography systems.
  • One study found unsatisfactory agreement between VMS+ and cardiac MRI for measuring right ventricle ejection fraction.
  • Initial cost may be slightly higher than current standard care due to additional time required for echocardiograms.
  • The interface on some VMS software (not explicitly VMS+) has been described as lacking color or contrast, and requiring time to learn.

Based on reviews from: Ventripoint Diagnostics Ltd., Vertex AI Search, Edison Awards, YouTube, NICE, QualityStocks, BioTuesdays, Reddit, TradingView News, Health Insight, Cardiologic, Capterra, G2

Last updated: 2026-07-20

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Ventripoint Medical System Plus (VMS+)

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

FDA
Ventripoint Medical System Plus (VMS+) 4.0 receives FDA 510(k) clearance
Ventripoint Medical System Plus (VMS+) 4.0 received 510(k) premarket notification clearance from the FDA on February 26, 2025. This regulatory announcement indicates the latest version of the system is cleared for market.
2025-02
FDA
Ventripoint Medical System Plus (VMS+) 3.0 receives FDA 510(k) clearance
The Ventripoint Medical System Plus (VMS+) 3.0, an adjunct to existing ultrasound imaging systems for 3D image processing of heart chambers, received 510(k) clearance from the FDA on October 16, 2019. It is indicated for use where Left Ventricle (LV), Right Ventricle (RV), Left Atrium (LA), and Right Atrium (RA) volumes and ejection fractions are desired.
2019-10
Investing News Network
5 Small Medical Device Companies
Ventripoint Diagnostics (TSXV:VPT,OTCQB:VPTDF) is highlighted as a small medical device company with its VMS+ 3.0 system, which uses AI reconstruction technology to produce 3D heart images for analyzing all four cardiac chambers. In August 2023, Ventripoint announced a new product with ASCEND Cardiovascular for improving diagnosis and monitoring of congenital heart disease.
2023-09
National Institute for Health and Care Excellence (NICE)
Ventripoint Medical System Plus for measuring heart volume and function
This briefing from NICE, published in November 2022, describes the Ventripoint Medical System Plus (VMS+) as an image analysis technology that uses 2D echocardiography to generate 3D models of the heart to measure heart volume and function. It is a CE marked class IIa medical device and is claimed to be faster and as accurate as cardiac MRI.
2022-11
MDPI (Encyclopedia)
Artificial Intelligence in Translational Medicine
This article from December 2021 mentions Ventripoint Medical System Plus (VMS+) 3.0 as an AI-powered tool used for measuring whole heart function using conventional ultrasound. It highlights the growing traction of AI in healthcare for improving patient outcomes and transforming medicine.
2021-12
Constat
Ventripoint Medical System Plus (VMS+) (K173810)
This entry details the premarket evidence for the Ventripoint Medical System Plus (VMS+) (K173810), cleared by the FDA on May 14, 2018. It describes the system as an adjunct to existing ultrasound imaging systems with accessories and proprietary software for evaluating heart chambers.
2018-05
X-ray Interpreter
Ventripoint Diagnostics | Radiology AI Companies
X-ray Interpreter provides an overview of Ventripoint Diagnostics and its VMS+ systems, including versions 3.0 and 4.0. It describes how the systems work as adjuncts to ultrasound imaging to reconstruct 3D heart models from 2D images, aiding in the measurement of heart chamber volumes and ejection fractions.
unknown

Videos

Product demos, reviews, and walkthroughs for Ventripoint Medical System Plus (VMS+).

View all on YouTube

Frequently Asked Questions

The VMS+ utilizes AI-powered Knowledge-Based Reconstruction (KBR) technology to transform standard 2D ultrasound scans into detailed 3D models of all four heart chambers. This allows for the calculation of volumetric measurements and ejection fractions with accuracy comparable to cardiac MRI, while also featuring AI-assisted point placement in VMS+ 4.0 to streamline image analysis.
VMS+ 4.0 has received a Medical Device License from Health Canada and regulatory clearance in the EU and UK, along with US FDA 510(k) clearance in February 2025. The system's design and development adhere to 21 CFR 820 Quality System Regulation and ISO 13485:2016 quality system standards, ensuring high safety and quality.
VMS+ is positioned as a faster, more affordable, and accessible alternative to cardiac MRI (cMRI), offering comparable accuracy for whole-heart volumetric measurements. It can be integrated with existing standard ultrasound systems from various vendors, making it a versatile diagnostic aid.
While specific pricing is not publicly detailed, VMS+ is described as a significantly more affordable alternative to cardiac MRIs, with some sources suggesting it's comparable to the cost of a standard ultrasound exam. This cost-effectiveness aims to make MRI-quality data more widely accessible for patient evaluation.
VMS+ functions as a diagnostic aid and requires healthcare professionals trained in cardiac sonography or echocardiography to operate it, including reviewing and refining AI-placed anatomical points. Although generally accurate, some studies have noted exclusions due to issues with VMS imaging, indicating that user expertise and image quality remain important factors.
VMS+ is designed to seamlessly integrate into the typical workflow of sonographers and cardiologists, operating as an adjunct to existing ultrasound imaging systems. Ventripoint provides face-to-face and remote training by clinical specialists, covering image acquisition and analysis, with initial on-site support included in the system's cost.
Yes, VMS+ is designed for full-scope use, from newborns to adults, and is particularly beneficial for patients who cannot undergo MRI, such as those with cardiac pacemakers or young children who may require sedation for an MRI. Its magnet-free sensors in VMS+ 4.0 further expand its applicability to patients with pacemakers.

Related Tools

EchoMD AutoEF
Caption Health (formerly Bay Labs, now part of GE HealthCare)
Cardiology AI
EchoMD AutoEF is an FDA-cleared AI software that automates the selection of echocardiogram clips and calculates left ventricular ejection fraction (EF), enhancing efficiency and accuracy in cardiac assessments.
ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm
Anumana, Inc.
Cardiology AI
An AI algorithm for screening cardiac amyloidosis using standard 12-lead ECGs.
DEEPVESSEL Plaque
Keya Medical Technology Co., Ltd.
Cardiology AI
An AI software platform for coronary plaque analysis and quantification from CT angiography.
WatchMate Software
Anumana, Inc.
Cardiology AI
Anumana is an AI-driven health technology company from nference, developing and delivering ECG algorithms enabling early diagnosis and intervention.
syngo.CT Coronary Cockpit
Siemens Healthineers
Cardiology AI
syngo.CT Coronary Cockpit is an AI-powered software tool by Siemens Healthineers for efficient and accurate CT coronary angiography analysis.
HeartLung AI-CVD®
HeartLung Corporation
Cardiology AI
HeartLung AI-CVD® is an FDA-cleared AI-powered quantitative imaging tool that provides automated CT-derived measurements for assessing cardiovascular and multisystem risks opportunistically.

See all Cardiology AI tools →

Suggest an Edit → | Last Verified: 2026-04-19 | First Added: 2026-04-19
AI Tool Finder
AI-powered search. Results may not be comprehensive.